Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality

Ruth Etzioni, Isabelle Durand-Zaleski, Iris Lansdorp-Vogelaar

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cancer interventions often disseminate in the population before evidence of their effectiveness is available. Population disease trends provide a natural experiment for assessing the characteristics of the disease and the potential impact of the intervention. We review models for extracting information from population data for use in economic evaluations of cancer screening interventions. We focus particularly on prostate-specific antigen (PSA) screening for prostate cancer and describe approaches that can be used to project the likely costs and benefits of competing screening policies. Results indicate that the lifetime probability of biopsy-detectable prostate cancer is 33%, the chance of clinical diagnosis without screening is 13%, and the average time from onset to clinical diagnosis is 14 years. Less aggressive screening policies that screen less often and use more conservative criteria (e.g., higher PSA thresholds) for biopsy referral may dramatically reduce PSA screening costs with modest impact on benefit.

Original languageEnglish (US)
Pages (from-to)117-123
Number of pages7
JournalJournal of the National Cancer Institute - Monographs
Issue number46
DOIs
StatePublished - Aug 1 2013
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Technology
Cost-Benefit Analysis
Mortality
Prostatic Neoplasms
Incidence
Population
Biopsy
Neoplasms
Early Detection of Cancer
Referral and Consultation
Costs and Cost Analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality. / Etzioni, Ruth; Durand-Zaleski, Isabelle; Lansdorp-Vogelaar, Iris.

In: Journal of the National Cancer Institute - Monographs, No. 46, 01.08.2013, p. 117-123.

Research output: Contribution to journalArticle

@article{ccc2502cd225499c9c1a65cf3955e391,
title = "Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality",
abstract = "Cancer interventions often disseminate in the population before evidence of their effectiveness is available. Population disease trends provide a natural experiment for assessing the characteristics of the disease and the potential impact of the intervention. We review models for extracting information from population data for use in economic evaluations of cancer screening interventions. We focus particularly on prostate-specific antigen (PSA) screening for prostate cancer and describe approaches that can be used to project the likely costs and benefits of competing screening policies. Results indicate that the lifetime probability of biopsy-detectable prostate cancer is 33{\%}, the chance of clinical diagnosis without screening is 13{\%}, and the average time from onset to clinical diagnosis is 14 years. Less aggressive screening policies that screen less often and use more conservative criteria (e.g., higher PSA thresholds) for biopsy referral may dramatically reduce PSA screening costs with modest impact on benefit.",
author = "Ruth Etzioni and Isabelle Durand-Zaleski and Iris Lansdorp-Vogelaar",
year = "2013",
month = "8",
day = "1",
doi = "10.1093/jncimonographs/lgt010",
language = "English (US)",
pages = "117--123",
journal = "NCI Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "46",

}

TY - JOUR

T1 - Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality

AU - Etzioni, Ruth

AU - Durand-Zaleski, Isabelle

AU - Lansdorp-Vogelaar, Iris

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Cancer interventions often disseminate in the population before evidence of their effectiveness is available. Population disease trends provide a natural experiment for assessing the characteristics of the disease and the potential impact of the intervention. We review models for extracting information from population data for use in economic evaluations of cancer screening interventions. We focus particularly on prostate-specific antigen (PSA) screening for prostate cancer and describe approaches that can be used to project the likely costs and benefits of competing screening policies. Results indicate that the lifetime probability of biopsy-detectable prostate cancer is 33%, the chance of clinical diagnosis without screening is 13%, and the average time from onset to clinical diagnosis is 14 years. Less aggressive screening policies that screen less often and use more conservative criteria (e.g., higher PSA thresholds) for biopsy referral may dramatically reduce PSA screening costs with modest impact on benefit.

AB - Cancer interventions often disseminate in the population before evidence of their effectiveness is available. Population disease trends provide a natural experiment for assessing the characteristics of the disease and the potential impact of the intervention. We review models for extracting information from population data for use in economic evaluations of cancer screening interventions. We focus particularly on prostate-specific antigen (PSA) screening for prostate cancer and describe approaches that can be used to project the likely costs and benefits of competing screening policies. Results indicate that the lifetime probability of biopsy-detectable prostate cancer is 33%, the chance of clinical diagnosis without screening is 13%, and the average time from onset to clinical diagnosis is 14 years. Less aggressive screening policies that screen less often and use more conservative criteria (e.g., higher PSA thresholds) for biopsy referral may dramatically reduce PSA screening costs with modest impact on benefit.

UR - http://www.scopus.com/inward/record.url?scp=84883047517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883047517&partnerID=8YFLogxK

U2 - 10.1093/jncimonographs/lgt010

DO - 10.1093/jncimonographs/lgt010

M3 - Article

C2 - 23962515

AN - SCOPUS:84883047517

SP - 117

EP - 123

JO - NCI Monographs

JF - NCI Monographs

SN - 1052-6773

IS - 46

ER -